Iza-bren Hits Recommended Phase 3 Dose in EGFR-Mutated NSCLC, Advancing to IZABRIGHT-Lung01
核心洞察
The EGFR (搜索) x HER3 (搜索) antibody-drug conjugate iza-bren (搜索) produced a 33.3% objective response rate at 2.5 mg/kg in the randomized dose-expansion cohort of a global Phase 1 study.
Median progression-free survival reached 6.9 months in patients who had all progressed on a third-generation EGFR (搜索) inhibitor, with nearly two-thirds also receiving platinum-based chemotherapy.
Mandatory primary G-CSF prophylaxis improved the hematologic safety profile, with no treatment-related deaths and only one discontinuation due to a treatment-related adverse event.
An investigational antibody-drug conjugate that simultaneously targets EGFR (搜索) and HER3 (搜索) has delivered encouraging clinical results in patients with previously treated EGFR-mutated non-small cell lung cancer (搜索) (NSCLC), supporting selection of 2.5 mg/kg as the recommended Phase 3 dose. The data, from the randomized dose-expansion cohort of a global Phase 1 study, were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) in Seoul, Republic of Korea.
The agent, iza-bren (搜索), is designed to bind both EGFR (搜索) and HER3 (搜索), two members of the ErbB receptor family that non-small cell lung cancer cells frequently exploit to survive treatment. It couples a bispecific antibody to a topoisomerase I inhibitor payload, directing cytotoxic cargo to cells expressing either receptor in an effort to concentrate toxicity within tumor tissue while sparing healthy cells relative to conventional chemotherapy. Targeting two receptors at once is intended to broaden coverage across heterogeneous tumors and reduce the chance that cancer cells escape treatment by downregulating a single target. HER3 has drawn particular attention because it is widely expressed in EGFR-mutated lung cancers and has been implicated in resistance to EGFR-targeted therapy.
Dose Finding and Efficacy
Dose finding was a central objective of the study, and the results revealed a clear relationship between dose level and clinical activity, with responses becoming more frequent as the dose increased. Three dose levels entered the randomized expansion cohort; 2.5 mg/kg, dosed on days one and eight of a three-week cycle, produced higher efficacy than the lower doses tested.
At that dose, the objective response rate reached 33.3 percent, the confirmed objective response rate — which requires shrinkage to be verified on a subsequent scan — stood at 29.6 percent, and median progression-free survival was 6.9 months.
The population enrolled was heavily pretreated. All patients had previously progressed on a third-generation EGFR (搜索) inhibitor, and nearly two-thirds had also received platinum-based chemotherapy, placing the agent in one of the most treatment-refractory settings in thoracic oncology. Osimertinib is the dominant third-generation EGFR inhibitor and is FDA-approved in both first-line and adjuvant settings, meaning a large and growing share of metastatic EGFR-mutated patients will eventually need a next option. The FDA granted iza-bren (搜索) Breakthrough Therapy Designation in August 2025 for patients with EGFR exon 19 deletions or exon 21 L858R mutations whose disease had progressed on a prior EGFR inhibitor.
Safety and Supportive Care
Safety has historically been the principal challenge for therapies directed at EGFR (搜索) and HER3 (搜索), because both receptors are expressed to some degree in normal tissues, including the skin, gastrointestinal tract, and blood-forming system. Earlier experience with the investigational conjugate raised concerns about hematologic toxicity, particularly declines in white blood cell counts that can leave patients vulnerable to infection.
The study addressed this risk directly by making primary prophylaxis with granulocyte colony-stimulating factor (G-CSF), a growth factor that stimulates white blood cell production, a mandatory part of the treatment protocol. This requirement was associated with an improved hematologic safety profile compared with previously reported experience, demonstrating that supportive care can meaningfully widen the therapeutic window of a potent targeted agent.
Beyond blood counts, the overall tolerability data supported continued development. No treatment-related deaths were observed across the study, and only one patient discontinued therapy because of a treatment-related adverse event — an unusually low discontinuation rate for an oncology drug in this class. Investigators characterized the safety profile as manageable.
Global Data and Resistance Rationale
The WCLC presentation adds a global dimension to the program. Earlier efficacy and safety signals for iza-bren (搜索) came primarily from Chinese patient cohorts; the Phase 1 randomized expansion presented by Alexander Spira, M.D., of NEXT Oncology Virginia (搜索) and Virginia Cancer Specialists (搜索) in Fairfax, Virginia, enrolled a global population and showed consistency with those earlier results. That consistency matters for a registrational strategy, since regulators in the United States and Europe typically want their own patient populations represented before an approval package is assembled.
The durability and breadth of responses also carry implications for how the field approaches resistance to EGFR (搜索)-targeted therapy. Resistance mechanisms after third-generation EGFR inhibitors are diverse, ranging from secondary mutations in EGFR itself to lineage shifts that transform tumor behavior entirely. A therapeutic approach that does not depend on a single resistance mechanism, but instead exploits persistent surface expression of EGFR and HER3 (搜索) to deliver chemotherapy directly to tumor cells, offers a way to sidestep much of that heterogeneity.
"These findings support continued development of iza-bren (搜索) and provide the rationale for advancing the 2.5 mg/kg regimen into the global Phase 3 IZABRIGHT-Lung01 trial for patients with previously treated EGFR (搜索)-mutated NSCLC," Spira said.
Next Steps in the Registrational Program
On the strength of these findings, investigators have selected 2.5 mg/kg as the recommended Phase 3 dose and are advancing the regimen into IZABRIGHT-Lung01, a global registrational trial designed to test the therapy in patients with previously treated EGFR (搜索)-mutated NSCLC. Registrational studies of this kind are the decisive step between experimental development and potential regulatory approval, and their design will determine whether the signal seen in the Phase 1 cohort holds up under controlled comparison.
The dual-targeting design is the rationale for describing iza-bren (搜索) as potentially first-in-class as an EGFR (搜索) x HER3 (搜索) antibody-drug conjugate, though that designation ultimately depends on what reaches approval first. The open question is whether the 2.5 mg/kg dose holds its efficacy advantage across the full breadth of IZABRIGHT-Lung01 enrollment, where patient heterogeneity and longer follow-up will test what the expansion cohort suggested. The path from a Phase 1 dose-expansion cohort to a registrational program is never guaranteed, and the history of oncology drug development includes early signals that failed to confirm in larger, randomized settings.